MARKET

APRE

APRE

Aprea Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.920
-0.120
-2.38%
Opening 13:20 06/18 EDT
OPEN
4.930
PREV CLOSE
5.04
HIGH
4.990
LOW
4.770
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
41.12
52 WEEK LOW
3.880
MARKET CAP
104.24M
P/E (TTM)
-1.9373
1D
5D
1M
3M
1Y
5Y
Implied Volatility Surging for Aprea (APRE) Stock Options
Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.
Zacks · 4h ago
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
Zacks · 1d ago
CureVac, Hecla Mining among premarket losers' pack
CureVac CVAC -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd CRTD -17% after proposing stock offeringNovan NOVN -14% after proposing capital raise.Torchlight Energy Resources TRCH -1...
Seekingalpha · 1d ago
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront.
Benzinga · 1d ago
STSA, AXLA, CVAC and CRBP among after-hours movers
Gainers: [[STSA]] +17.8%. [[CLVS]] +6.4%. [[AXLA]] +5.5%. [[RUN]] +4.1%. [[STRR]] +3.1%.Losers: [[CVAC]] -49.7%. [[CATB]] -4.9%. [[CRBP]] -3.8%. [[LXRX]] -3.8%. [[APRE]] -3.5%.
Seekingalpha · 1d ago
Aprea Therapeutics Shares Rise 18% on Trial for Leukemia Treatment
marketwatch.com · 1d ago
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc.
Benzinga · 2d ago
Opthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losers
Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%, Fusion Pharmaceuticals (FUS...
Seekingalpha · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APRE. Analyze the recent business situations of Aprea Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APRE stock price target is 7.25 with a high estimate of 10.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 8.95M
% Owned: 42.25%
Shares Outstanding: 21.19M
TypeInstitutionsShares
Increased
20
1.92M
New
16
825.81K
Decreased
16
1.57M
Sold Out
13
2.52M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.71%
Pharmaceuticals & Medical Research
-0.97%
Key Executives
Chairman/President/Chief Executive Officer/Director
Christian Schade
Chief Financial Officer/Senior Vice President/Secretary
Scott Coiante
Senior Vice President/Chief Scientific Officer
Lars Abrahmsen
Senior Vice President
Eyal Attar
Senior Vice President
Gregory Korbel
Other
Gregory Wessels
Lead Director/Independent Director
John Henneman
Independent Director
Johan Christenson
Independent Director
Michael Kelly
Independent Director
Fouad Namouni
Independent Director
Richard Peters
Independent Director
Bernd Seizinger
No Data
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Webull offers kinds of Aprea Therapeutics Inc stock information, including NASDAQ:APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.